Skip to content
Inciteful Med

Pregnancy and Family Planning: Managing Anti-SSA Risks

Last updated:

Women with Anti-SSA (Ro) antibodies face a risk of fetal congenital heart block (1-2% for first pregnancies). Taking hydroxychloroquine significantly lowers this risk. Strict weekly monitoring with fetal echocardiograms from weeks 16 to 26 is essential to detect and manage heart rhythm changes early.

Key Takeaways

  • • Anti-SSA (Ro) antibodies carry a 1-2% risk of causing fetal congenital heart block in a first pregnancy.
  • • Hydroxychloroquine is a safe medication that significantly reduces the risk of heart block recurrence.
  • • Weekly fetal echocardiograms are critical between weeks 16 and 26 to detect heart rhythm changes early.
  • • Neonatal lupus rash is a temporary condition that resolves naturally within 4 to 6 months.
  • • Complete congenital heart block is usually irreversible and typically requires a permanent pacemaker.

For women with Sjögren’s Syndrome, pregnancy is usually very successful. However, if you have Anti-SSA (Ro) or Anti-SSB (La) antibodies, there are specific risks to the fetus that require careful, specialized monitoring. These antibodies can cross the placenta and potentially interfere with the development of the fetal heart’s electrical system [1][2].

The Main Risk: Congenital Heart Block (CHB)

The most significant risk associated with these antibodies is Congenital Heart Block (CHB). This occurs when maternal antibodies cause inflammation and scarring in the fetus’s heart, blocking the electrical signals that tell it to beat [1][3].

  • The Risk for a First Pregnancy: For a woman with these antibodies who has never had an affected child, the risk of CHB is low, estimated at 1% to 2% [4][5].
  • The Recurrence Risk: If you have previously had a child with heart block, the risk for subsequent pregnancies increases significantly to approximately 18% to 20% [3][6][7].

Hydroxychloroquine (HCQ): A Vital Shield

Research has shown that Hydroxychloroquine (HCQ) is a powerful tool for reducing the risk of CHB [8][9].

  • Primary Prevention: While evidence is strongest for preventing recurrence, HCQ is also widely recommended for first pregnancies to potentially lower the risk [10].
  • Preventing Recurrence: For mothers who have already had an affected child, taking HCQ can reduce the risk of it happening again by more than 50% [8][7].
  • Safety: HCQ is considered safe during pregnancy and is the most evidence-supported medication for preventing these complications [11][10].

The Monitoring Protocol: Weeks 16 to 26

Because the fetal heart is most vulnerable to these antibodies during the middle of pregnancy, a strict monitoring schedule is essential.

  • Fetal Echocardiograms: Most experts recommend weekly fetal echocardiograms starting at Week 16 and continuing through Week 26 [12][13].
  • Why the Frequency? Heart block can progress rapidly. If caught at an early stage (like 1st or 2nd-degree block), doctors may be able to intervene with medications to prevent it from becoming permanent 3rd-degree block [14][15].

Neonatal Lupus Rash: A Temporary Condition

Another common manifestation of these antibodies is the Neonatal Lupus (NNL) rash.

  • Appearance: This typically looks like red, ring-shaped (annular) spots on the face or scalp [16][17].
  • The “Good” News: Unlike CHB, this rash is temporary. It usually resolves on its own within 4 to 6 months as the mother’s antibodies naturally clear from the baby’s system [18][19]. It does not mean the child has systemic lupus or will have a lifelong autoimmune disease [20][21].

Prognosis for CHB

If a baby is born with complete (3rd-degree) heart block, the condition is usually irreversible [22][1].

  • Management: Most children born with complete CHB will require a permanent pacemaker, often implanted within the first few weeks or months of life [1][23].
  • Long-Term: With a pacemaker and specialized care from a pediatric cardiologist, these children can lead full, active lives [24][25].

Pregnancy Planning Checklist

  • [ ] Test Antibody Levels: Confirm your Anti-SSA (Ro) and Anti-SSB (La) status [26].
  • [ ] Consult MFM: Meet with a Maternal-Fetal Medicine (High-Risk OB) specialist before conceiving [27].
  • [ ] Review Medications: Ensure you are on a pregnancy-safe dose of HCQ [11].
  • [ ] Schedule Echos: Pre-book your weekly echocardiograms for the 16-26 week window.

Frequently Asked Questions

What is the risk of heart block with Anti-SSA antibodies?
For women with these antibodies who have never had an affected child, the risk of the baby developing congenital heart block is approximately 1% to 2%. If you have previously had a child with heart block, the risk for future pregnancies rises to about 18% to 20%.
Does hydroxychloroquine help prevent congenital heart block?
Yes, research shows that taking Hydroxychloroquine (HCQ) significantly reduces the risk. For mothers who have previously had a child with heart block, HCQ can lower the recurrence risk by more than 50%. It is considered safe and is widely recommended during pregnancy.
When do I need fetal echocardiograms during pregnancy?
Doctors typically recommend weekly fetal echocardiograms starting at week 16 and continuing through week 26. This period is when the fetal heart is most vulnerable, and frequent monitoring allows doctors to detect heart rhythm changes as early as possible.
Is neonatal lupus rash permanent?
No, the neonatal lupus rash is temporary. It typically resolves on its own within 4 to 6 months as the mother's antibodies clear from the baby's system. It does not mean the child has systemic lupus or will have a lifelong autoimmune disease.
Can congenital heart block be reversed?
If the heart block progresses to a complete (3rd-degree) block, it is usually irreversible and requires a pacemaker. However, if caught at an earlier stage (1st or 2nd-degree block) during monitoring, doctors may be able to intervene with medications to prevent it from becoming permanent.

Questions for Your Doctor

  • • Can we confirm my exact antibody status (Anti-Ro52 vs. Anti-Ro60)? How does this affect my specific risk for CHB?
  • • Who is the Maternal-Fetal Medicine (MFM) specialist or cardiologist that will be performing my weekly fetal echocardiograms?
  • • Should I increase my dose of Hydroxychloroquine to 400mg daily if it is currently lower, and how early in the pregnancy should I start?
  • • If we detect a change in the fetal heart rhythm (like 1st or 2nd-degree block), what is our immediate protocol for intervention?
  • • What pediatric cardiologists do you recommend we consult with before the baby is born?

Questions for You

  • • Have any of your previous children had a skin rash or heart issues at birth?
  • • Are you prepared for the schedule of weekly fetal echocardiograms between weeks 16 and 26?
  • • Have you discussed your desire to conceive with both your rheumatologist and your OB/GYN to coordinate care?
  • • How are you managing the stress of pregnancy monitoring, and do you have a support system in place?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Neonatal lupus erythematosus - practical guidelines.

    Derdulska JM, Rudnicka L, Szykut-Badaczewska A, et al.

    Journal of perinatal medicine 2021; (49(5)):529-538 doi:10.1515/jpm-2020-0543.

    PMID: 33470961
  2. 2

    Obstetric and perinatal outcome in anti-Ro/SSA-positive pregnant women: a prospective cohort study.

    Martínez-Sánchez N, Pérez-Pinto S, Robles-Marhuenda Á, et al.

    Immunologic research 2017; (65(2)):487-494 doi:10.1007/s12026-016-8888-5.

    PMID: 28138914
  3. 3

    Facilitation of Vaginal Delivery in an Infant with Complete Heart Block Secondary to Maternal Anti-Ro Antibodies.

    Thornton E, Tripathi L, Shebani S, et al.

    Case reports in obstetrics and gynecology 2017; (2017()):8352320 doi:10.1155/2017/8352320.

    PMID: 29359058
  4. 4

    Identification of discrete epitopes of Ro52p200 and association with fetal cardiac conduction system manifestations in a rodent model.

    Hoxha A, Ruffatti A, Ambrosi A, et al.

    Clinical and experimental immunology 2016; (186(3)):284-291 doi:10.1111/cei.12854.

    PMID: 27548532
  5. 5

    Routine repeated echocardiographic monitoring of fetuses exposed to maternal anti-SSA antibodies: time to question the dogma.

    Costedoat-Chalumeau N, Morel N, Fischer-Betz R, et al.

    The Lancet. Rheumatology 2019; (1(3)):e187-e193 doi:10.1016/S2665-9913(19)30069-4.

    PMID: 38229394
  6. 6

    Autoimmune congenital heart block and primary Sjögren's syndrome: characterisation and outcomes of 49 cases.

    Brito-Zerón P, Pasoto SG, Robles-Marhuenda A, et al.

    Clinical and experimental rheumatology 2020; (38 Suppl 126(4)):95-102.

    PMID: 33025893
  7. 7

    Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers.

    Izmirly P, Kim M, Friedman DM, et al.

    Journal of the American College of Cardiology 2020; (76(3)):292-302 doi:10.1016/j.jacc.2020.05.045.

    PMID: 32674792
  8. 8

    Neonatal lupus erythematosus - prevention is better than cure.

    Liszewska A, Woźniacka A

    Postepy dermatologii i alergologii 2022; (39(6)):1021-1026 doi:10.5114/ada.2022.122601.

    PMID: 36686025
  9. 9

    Treatment options for preventing autoimmune-mediated congenital heart block: a systematic review.

    Agarwal A, Skoutelis N, Zhou Y, et al.

    Archives of disease in childhood 2025; (110(7)):556-565 doi:10.1136/archdischild-2024-327570.

    PMID: 39890428
  10. 10

    Society for Maternal-Fetal Medicine Consult Series #64: Systemic lupus erythematosus in pregnancy.

    , Silver R, Craigo S, et al.

    American journal of obstetrics and gynecology 2023; (228(3)):B41-B60 doi:10.1016/j.ajog.2022.09.001.

    PMID: 36084704
  11. 11

    Hydroxychloroquine in systemic lupus erythematosus, anti-SSA/SSB, and antiphospholipid antibody-positive pregnancies.

    Saleh ZF, Somers EC, Romero VC, Marder W

    American journal of obstetrics and gynecology 2026; (234(1)):7-20 doi:10.1016/j.ajog.2025.09.002.

    PMID: 40930382
  12. 12

    Use of Polynomial Reference Ranges for Atrioventricular Intervals Assessed by Fetal Echocardiography in Anti-Ro/SSA Antibody-Positive Pregnancies to Exclude Fetal Heart Blocks: A Pilot Study.

    Mosimann B, Amylidi-Mohr S, Surbek D, et al.

    Fetal diagnosis and therapy 2023; (50(6)):422-429 doi:10.1159/000531780.

    PMID: 37497922
  13. 13

    Congenital Complete Atrioventricular Heart Block in a Pregnant Woman with Sjögren Syndrome: Prenatal Care Follow-Up and the Challenge of Intrauterine Treatment.

    Carrilho MC, Bravo-Valenzuela NJ, Araujo Júnior E

    Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia 2020; (42(4)):228-232 doi:10.1055/s-0040-1709738.

    PMID: 32330965
  14. 14

    Novel approaches to the surveillance and management of fetuses at risk for anti-Ro/SSA mediated atrioventricular block.

    Kaplinski M, Cuneo BF

    Seminars in perinatology 2022; (46(4)):151585 doi:10.1016/j.semperi.2022.151585.

    PMID: 35410713
  15. 15

    Reducing the burden of surveillance in pregnant women with no history of fetal atrioventricular block using the negative predictive value of anti-Ro/SSA antibody titers.

    Kaizer AM, Lindblade C, Clancy R, et al.

    American journal of obstetrics and gynecology 2022; (227(5)):761.e1-761.e10 doi:10.1016/j.ajog.2022.05.071.

    PMID: 35690080
  16. 16

    Neonatal lupus erythematosus: a cutaneous cases based update.

    Savino F, Viola S, Tarasco V, et al.

    Italian journal of pediatrics 2016; (42()):1 doi:10.1186/s13052-015-0208-5.

    PMID: 26743447
  17. 17

    Cutaneous Neonatal Lupus Erythematosus: A Case Report.

    Ramphul K, Mejias SG, Ramphul-Sicharam Y

    Cureus 2018; (10(2)):e2212 doi:10.7759/cureus.2212.

    PMID: 29686954
  18. 18

    Periorbital hypopigmentation and telangiectasias: Clues to diagnosing neonatal lupus in skin of color.

    Kleitsch J, Mazori DR, Derrick KM, et al.

    Pediatric dermatology 2021; (38 Suppl 2()):135-136 doi:10.1111/pde.14674.

    PMID: 34250633
  19. 19

    Spontaneously Resolved Suspected Hemophagocytic Lymphohistiocytosis or Macrophage Activating Syndrome Associated with Neonatal Lupus Erythematosus: A Case Report.

    Ishizuka K, Shigemori H, Ochiai S, et al.

    The Tokai journal of experimental and clinical medicine 2024; (49(2)):53-56.

    PMID: 38904234
  20. 20

    Neonatal lupus erythematosus: a review of 123 cases in China.

    Li YQ, Wang Q, Luo Y, Zhao Y

    International journal of rheumatic diseases 2015; (18(7)):761-7 doi:10.1111/1756-185X.12652.

    PMID: 26171790
  21. 21

    Retrospective, single-center case series of neonatal lupus.

    Wang YA, Sibbald C, Moon AT

    Pediatric dermatology 2020; (37(3)):484-489 doi:10.1111/pde.14132.

    PMID: 32110851
  22. 22

    A 10-year retrospective study of neonatal lupus erythematous in China.

    Yu Y, Du L, Pan J, et al.

    Asian Pacific journal of allergy and immunology 2016; (34(2)):174-8 doi:10.12932/AP0671.34.2.2016.

    PMID: 27007840
  23. 23

    Placement of permanent pacemaker in a low-birth-weight infant with congenital heart block: a case report.

    Ashraf N, Fatima R, Atiq M, Amanullah M

    JPMA. The Journal of the Pakistan Medical Association 2023; (73(5)):1113-1116 doi:10.47391/JPMA.6674.

    PMID: 37218247
  24. 24

    Neonatal lupus erythematosus presenting with congenital heart block: clinical characteristics and follow-up.

    Sun W, Zhou M, Li Y, et al.

    Clinical rheumatology 2025; (44(4)):1581-1587 doi:10.1007/s10067-025-07381-4.

    PMID: 40056332
  25. 25

    Clinical characteristics of neonatal lupus erythematosus complicated by congenital heart block: a multi-center retrospective study in East China.

    Jin X, Sun W, Li Y, et al.

    Scientific reports 2025; (15(1)):14031 doi:10.1038/s41598-025-98368-3.

    PMID: 40269139
  26. 26

    Low prevalence of anti-SSA (anti-Ro) and anti-SSB (anti-La) autoantibodies in female patients with rheumatoid arthritis with a wish to conceive.

    Smeele HTW, Schreurs MWJ, Costedoat-Chalumeau N, et al.

    RMD open 2021; (7(2)) doi:10.1136/rmdopen-2021-001727.

    PMID: 34244382
  27. 27

    The prevention, screening and treatment of congenital heart block from neonatal lupus: a survey of provider practices.

    Clowse MEB, Eudy AM, Kiernan E, et al.

    Rheumatology (Oxford, England) 2018; (57(suppl_5)):v9-v17 doi:10.1093/rheumatology/key141.

    PMID: 30137589

This guide explains pregnancy risks associated with Anti-SSA antibodies for educational purposes. Always consult your rheumatologist and obstetrician for personal medical advice.

Stay up to date

Get notified when new research about Sjögren's Syndrome is published.

No spam. Unsubscribe anytime.